繁体中文
设为首页
加入收藏
当前位置:缺药登记 >> Zophren

Zophren

ID号:401  发布日期: 2011-10-22    截止日期: 不限  地区:全国 浏览次数:413

Zophren - General Information:

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]


Related offers from our Drug Store:

  Zofran (Ondansetron) - 38.64
Zofran is used for preventing nausea and vomiting due to cancer chemotherapy or surgery. It may also be used for other conditions as determined by your doctor.

* >> all this drugs based on Ondansetron (usually they can be used instead of Zophren)

Related offer from MedStore:

  Generic Zofran (Ondansetron) - 8mg 20 pills 70.80
Zofran (Ondansetron) is an antiemetic used to prevent nausea and vomiting. It may also be used for other conditions as determined by your doctor.

Pharmacology:

Zophren is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Zophren is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.

Zophren for patients

Zophren Interactions

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.

Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3

Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5

Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.

In a crossover study in 76 pediatric patients, I.V. ondansetron did not increase blood levels of high-dose methotrexate.

Zophren Contraindications

Ondansetron injection and Ondansetron injection premixed are contraindicated for patients known to have hypersensitivity to the drug.

Additional information about Zophren

Zophren Indication: For treatment of chemotherapy-induced nausea and vomiting
Mechanism Of Action: Zophren is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Zophren works by blocking the reception of serotonin at these 5-HT3 receptors.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Ondansetron
Synonyms: Not Available
Drug Category: Anti-anxiety Agents; Antipsychotics; Antipruritics; Antiemetics; Serotonin Antagonists
Drug Type: Small Molecule; Approved
Other Brand Names containing Ondansetron: Zofran; Zofran ODT; Zophren; Zudan; PMS-ondansetron; Ratio-ondansetron; Sandoz ondansetron; PHL-ondansetron; Novo-ondansetron; Apo-ondansetron;
Absorption: Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.
Toxicity (Overdose): Low blood pressure and fainting, sudden blindness, severe constipation
Protein Binding: 70%-76% (Plasma protein binding)
Biotransformation: Hepatic
Half Life: 5.7 hours
Dosage Forms of Zophren: Solution Intravenous
Liquid Oral
Liquid Intravenous
Tablet Oral
Chemical IUPAC Name: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Chemical Formula: C18H19N3O
Ondansetron on Wikipedia: http://en.wikipedia.org/wiki/Ondansetron
Organisms Affected: Humans and other mammals

联系方式
联系人:admin
电 话:
地 址:
E-mail:
Q Q:
发布人信息
发布人:admin
目前身份:
最后登录:
E-mail:
查看用户发布的所有信息 >>

本类最新信息

· 首个抗晚期卵巢癌新药Lynpar...
· MabCampath(Alemtuzumab(Ge...
· 伏立诺他胶囊Zolinza(vorino...
· 提供全球稀药目录表
· 低价供应全球原研药品(2014)
· 盘点2013年美国FDA批准的新药
· Jevtana(cabazitaxel)注射剂
· 2011年12月至2012年7月获得F...
· MANNITOL 25% 50ML/VIAL(甘露...
· 凡瑞克(相当于美国的LETAIRI...

本类推荐信息

· 首个抗晚期卵巢癌新药Lynpar...
· MabCampath(Alemtuzumab(Ge...
· 伏立诺他胶囊Zolinza(vorino...
· 提供全球稀药目录表
· 低价供应全球原研药品(2014)
· 盘点2013年美国FDA批准的新药
· Jevtana(cabazitaxel)注射剂
· 2011年12月至2012年7月获得F...
· MANNITOL 25% 50ML/VIAL(甘露...
· 凡瑞克(相当于美国的LETAIRI...

相关信息